Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Health Robotics Issues Price Increase in Compliance With The Patient Protection and Affordable Care Act (ACA)

December 27, 2012

BOZEN, Sud-Tirol, Italy, December 27, 2012 /PRNewswire/ –

Health Robotics today announced that, effective January 1, 2013, it will fully comply
with The Patient Protection and Affordable Care Act (ACA), including maximum health
insurance benefits for its USA-based employees. Health Robotics is hopeful that its
USA-based customers understand the need for small companies such as Health Robotics to
transfer these additional operating costs and ACA’s mandatory excise [sales] taxes on
FDA-regulated medical devices equally to both its USA not-for-profit [tax-exempt
customers] and for-profit customers, effective March 1, 2013.

Gaspar DeViedma, Health Robotics’ Executive Vice President and Board Member, stated:
“Although USA-based operating companies may opt out of certain ACA mandates such as health
insurance coverage by hiring part-time employees or by other well documented methods,
Health Robotics recently made a decision after the November 6, 2012 elections to fully
comply with the ACA given the life-critical nature of our business. In order to offer our
prospective customers a reasonable time to obtain approval of their pending budgets, the
price increase shall be effective for all contracts/orders received on or after March 1,
2013, with all current quotes expiring thereafter, or subject to price modifications that
reflect the ACA.”

About Health Robotics:

Founded in 2006 and now reaching well over 80% global market share, Health Robotics is
the undisputed leading supplier of life-critical intravenous medication robots, providing
over 300 hospital installations in 5 continents with robotics-based technology and fully
integrated clinical software automation solutions. Health Robotics’ second generation
solutions [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through
scientific and peer-reviewed studies[1],[2]] to greatly contribute to ease hospitals’
growing pressures to improve patient safety[1], increase throughput and contain costs[1].
Through the effective and efficient production of sterile, accurate, tamper-evident and
ready-to-administer IVs, Health Robotics’ medical devices and integrated workflow
solutions help hospitals eliminate life-threatening drug[1] and diluent[1] exchange
errors, improve drug potency[2], decrease other medical mistakes and sterility risks, work
more efficiently[1], reduce waste and controlled substances’ diversion, and diminish the
gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff.
For more information, please visit: http://www.health-robotics.com

————————————————–

1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger,
Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and
Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard
Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.

2. Validation of an automated method for compounding monoclonal antibody patient
doses: case studies of Avastin(R), Remicade(R), and Herceptin(R). Peters, Capelle,
Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.

        For additional information, please contact:

        Claudia Perez
        perez@health-robotics.com
        Phone +1-786-417-1251

SOURCE Health Robotics


Source: PR Newswire